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The last two decades have seen extraordinary changes in
physicians’ attitudes toward and approach to the syndrome of
congestive heart failure (CHF). Research into etiology and
pathophysiology, development of powerful diagnostic tools
that provide insights into pathophysiology and new therapeutic
approaches effective in ameliorating symptoms and prolonging
life all contribute to this change. Echocardiography is uniquely
suited to evaluate the anatomical and functional cardiac
abnormalities in CHF. In this editorial, the term “echocardi-
ography” is used to indicate the Doppler echocardiographic
study as Doppler interrogation is essential to study valvular
function and estimate diastolic function. It provides valuable
information in reference to the diagnosis, prognosis and
therapeutic approaches to this very common syndrome. The
clinical utility of echocardiography in patients known or sus-
pected of having congestive heart failure, the ease with which
it can be obtained, and the widespread availability and safety of
the procedure have made it (except for the electrocardiogram)
the most frequently used cardiovascular diagnostic technique,
resulting in the largest expenditure for any cardiovascular
diagnostic test.
Evaluating the utility of a diagnostic, in contrast to a
therapeutic intervention, is a daunting task (1).
Two widely cited guidelines, one a consensus-based docu-
ment (2) and the other an “evidence-based” document (3),
recommend that echocardiography be an integral part of the
evaluation of the patient with CHF. In this era of so-called
evidence-based, cost-effective medicine, it is desirable to learn
whether guidelines are effective in enhancing the quality of
care.
In this issue of the Journal, Senni and colleagues (4) report
the use and impact of echocardiography in the 216 patients
with newly diagnosed congestive heart failure, using the Fra-
mingham criteria, in Olmstead County, Minnesota, in 1991.
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Data from the unique Rochester Epidemiologic Program were
used. They compared a variety of patient characteristics and
the outcome of the 137 patients who underwent echocardiog-
raphy within 3 weeks of the episode of congestive heart failure
(Echocardiography group) with 79 patients (37% of the sam-
ple) who did not have such an echocardiogram (No-
Echocardiography group). The principal end point was mor-
tality. Although crude survival was not significantly different
between the two groups adjusting for baseline differences in
age, New York Heart Association (NYHA) functional class,
and sex by multivariate analysis, there was a lower risk of death
in the Echocardiography group (RR 5 0.607, p 5 0.017). This
is an unexpected result.
Although patients in the No Echocardiography group were
slightly older (mean age 80 vs. 76 years), the Echocardiography
group patients had markers of more severe congestive heart
failure. Statistically, more in the Echocardiography group were
in-patients who had higher NYHA class, had far more frequent
gallop sounds and had greater changes on chest X-ray film
(pulmonary venous hypertension, interstitial pulmonary edema
and bilateral pleural effusions). In addition, a single but
important measure of co-morbidity, creatinine of greater than
2 mg/dl, was statistically more frequent in the Echocardiogra-
phy group. Of particular importance in assessing mortality
as an outcome, the Echocardiography group patients were
statistically more likely to get digoxin, angiotensin-converting
enzyme (ACE) inhibitor, warfarin and (although nonsta-
tistically significant) a diuretic. The investigators’ conclusion
that survival after the adjustments was lower in the No-
Echocardiography group than in the Echocardiography group
is warranted by the data, but why the difference exists needs
explanation.
The current report has the important advantage of being
population based; the entire population of Olmstead County
(more than 100,000 inhabitants) were surveyed, and in-patient
as well as out-patient cases of congestive heart failure are
included. This has the potential to avoid selection bias al-
though the generalizability of the information must be under-
taken cautiously as the ethnicity and diversity of the United
States is not reflected because Olmstead County is overwhelm-
ingly white (96%). In addition, retrospective studies are always
subject to diagnostic error despite the most thoughtful and
fastidious chart review. Although using the Framingham diag-
nostic criteria is a reasonable approach there is considerable
subjectivity in assessing a number of the major criteria whether
they be symptoms, presence of a third heart sound or an
estimate of central venous pressure of more than 16 cm of
water, and these major diagnostic criteria have considerable
temporal variation. Much has changed since these criteria were
formulated in 1971. In the studies of Marantz (4), 407 patients
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were prospectively evaluated using three clinical classifications
of CHF (Framingham, Boston, and Duke criteria) compared
to left ventricular ejection fraction determined by radionuclide
triculography. They concluded that the definitions had varying
utility depending on the population being examined. In an-
other study (5), they reviewed the early heart failure trials in
reference to CHF classification and found wide disparity. Their
overall conclusion that a combination of clinical features and
an objective measure of cardiac performance are needed to
diagnose congestive heart failure is a sound one and raises the
question: Should echocardiographic abnormalities be a part of
the definition of congestive heart failure?
The increased mortality in the No-Echocardiography group
patients who had clinical markers of less severe cardiovascular
disease is surprising and emphasizes (as the authors discuss)
shortcomings of this retrospective study. Most important are
potential differences in baseline co-morbidity in this very old
population. A variety of fatal conditions may have been
present in the No-Echocardiography group and accounted for
the increased mortality. The cause of death was not studied,
and a cardiac cause for death cannot be assumed in patients
with CHF whose mean age at time of entry is 80 years. The
mean difference of 4 years in this older age group is important
biologically and emphasizes the need to consider competing
risks, the situation when the establishment of a new diagnosis
(in this case CHF) has much less effect on long-term mortality
(5). Not only is co-morbidity much greater with increasing age,
but the effect of old age per se and the lack of physiologic
reserve both come into play.
Of major importance, the data suggest that knowledge
obtained from the echocardiogram was the reason why the
Echocardiography group had better survival. Patients in the
Echocardiography group were treated more frequently with
the three major classes of drugs known to improve symptoms—
digoxin, ACE inhibitor, and diuretic—and much more fre-
quently with the ACE inhibitor (53% vs. 28%), the drug known
to prolong life in congestive heart failure. Nine Echocardiog-
raphy group patients underwent cardiac surgery perhaps as a
direct result of information uncovered by echocardiography.
Although this represents only 6% of the sample, with such a
small sample size these nine patients could be responsible for
the improved outcome for the Echocardiography group if
there was a mortality benefit from surgery. Data in the report
do not allow a judgment as to which of these possibilities—or
a combination of possibilities—might explain the differences.
Additional features could help explain the outcome and
also the question: Who provided care for the patients? Cardi-
ologists, particularly those with special knowledge and interest
in CHF, have been shown to provide different care and derive
better outcomes than noncardiologists (6–10). What was the
pathophysiology? On the basis of echocardiographic can assess
diastolic and systolic dysfunction. Patients with diastolic dys-
function generally have better outcomes than do patients with
systolic dysfunction (11). Certainly, the greater the degree of
systolic dysfunction, the poorer the outcome, so that estima-
tion of ejection fraction is, of course, a critical variable in
prognosis.
When differences that are possibly related to a lack of
balance in important baseline variables and/or treatment dif-
ferences are judged to be the explanation of an outcome, it is
usual to call for a randomized controlled trial. In the evalua-
tion of a diagnostic test or a management strategy, in contrast
to the short-term evaluation of a therapeutic intervention,
randomized controlled trials are ordinarily not feasible and
probably not the most appropriate mechanism to evaluate a
diagnostic test. Observational databases, appropriately con-
structed, utilizing quantitative epidemiological methods and
sophisticated statistical approaches to assess outcomes are not
only justified but preferred (12). In reference to the current
report, the inadequate information on important baseline
variables in this elderly population and inability to assess the
cause of death are major drawbacks, as was cited, and the
sample was relatively small. However, these issues can be
overcome by more fastidious collection of data prospectively
and specific efforts to assess the cause of death, always a
difficult issue, but differentiating cardiac death from other
causes is usually possible.
What has the study taught us? The work of Senni and her
colleagues reminds us that retrospective analyses which appro-
priately link existing databases can provide useful insights
regarding the manner in which guidelines are being utilized
and provide persuasive suggestions concerning how they influ-
ence patient care. Even with thoughtful, detailed analyses, the
limitations of such an approach, however, are abundantly
apparent. Despite these limitations, the strong suggestion that
echocardiography as a part of the workup of new-onset
congestive heart failure is underutilized and improves care and
outcome seems reasonable.
What must we do to learn more? To study outcomes
initially, whether therapies or the more difficult area of use of
“tests,” disease-specific, detailed, prospective data collection is
a key to appropriate interpretation. The Rochester Epidemi-
ology Project is unique (13,14), but other databases could be
similarly studied. However, to clarify the problem, details
about the spectrum of etiology of congestive heart failure,
much more detail about echocardiographic findings in the
form of pathophysiology and anatomical change disease as well
as details concerning mode of death are all critical. Beyond
that, the evaluation of echocardiography as a test to improve
outcome almost certainly will require broader and “softer” end
points, not just mortality, to be evaluated. Hospitalization for
episodes of congestive heart failure was a particularly valuable
end point in the SOLVD Prevention Trial (15) and the DIG
trial (16). Not only do fewer hospitalizations improve the
patient’s lifestyle but they greatly reduce the expense of caring
for this very costly syndrome. In addition, because the vast
majority of patients who have CHF are elderly, information
about functional status and ability to continue to live indepen-
dently would be important. Such an approach would provide
an important first step in a very complicated process—that is,
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evaluating the use of a test, echocardiography, in the treatment
of a complicated syndrome, namely congestive heart failure.
Senni and her colleagues deserve our thanks for providing
a stimulating report. We hope others will pursue additional
follow-up studies despite the considerable obstacles that exist
in evaluating a diagnostic test.
The review and critique of Benjamin F. Byrd III is appreciated.
References
1. Douglas PS. Justifying echocardiography: the role of outcomes research in
evaluating a diagnostic test. J Am Soc Echocardiographycardiogr 1996;9:
577–81.
2. Williams JF, Bristow MR, Fowler MB, et al. Guidelines for the evaluation
and management of heart failure. Report of the American College of
Cardiology/American Heart Association Task Force on Practice Guidelines
(Committee on Evaluation and Management of Heart Failure). Circulation
1995;92:2764–84.
3. Konstam MA, Dracup K, Bottorff MB, et al. Heart Failure: Evaluation and
Care of Patients with Left Ventricular Systolic Dysfunction. Clinical Practice
Guideline No. 11. Rockville, Maryland: Agency for Health Care Policy and
Research, 1994:37–39.
4. Marantz PR, Tobin JN, Wassertheil-Smoller S, et al. The relationship
between left ventricular systolic function and congestive heart failure
diagnosed by clinical criteria. Circulation 1988;3:607–12.
5. Marantz PR, Alderman MH, Tobin JN. Diagnostic heterogeneity in clinical
trials for congestive heart failure. Ann Intern Med 1988;109:55–61.
6. Senni M, Rodeheffer RJ, Tribouilloy CM, et al. Use of echocardiography in
the management of congestive heart failure in the community. J Am Coll
Cardiol 1999;33:164–70.
7. Welch HG, Albertsen PC, Nease RF, et al. Estimating treatment benefits
for the elderly: the effect of competing risks. Ann Intern Med 1996;124:
577– 84.
8. Chin MH, Wang JC, Zhang JX, Lang RM. Utilization and dosing of
angiotensin-converting enzyme inhibitors for heart failure: effect of physician
specialty and patient characteristics. J Gen Intern Med 1997;12:563–6.
9. Edep ME, Shah NB, Tateo IM, Massie BM. Differences between primary
care physicians and cardiologists in management of congestive heart failure:
relation to practice guidelines. J Am Coll Cardiol 1997;30:518–26.
10. Reis SE, Holubkov R, Edmundowicz D, et al. Treatment of patients
admitted to the hospital with congestive heart failure: specialty-related
disparities in practice patterns and outcomes. J Am Coll Cardiol 1997;30:
733–8.
11. Hanumanthu S, Butler J, Chomsky D, Davis S, Wilson JR. Effect of a heart
failure program on hospitalization frequency and exercise tolerance. Circu-
lation 1997;96:2842–8.
12. Fonarow GC, Stevenson LW, Walden JA, et al. Impact of a comprehensive
heart failure management program on hospital readmission and functional
status of patients with advanced heart failure. J Am Coll Cardiol 1997;30:
725–32.
13. Dauterman KW, Massie BM, Gheorghiade M. Heart failure associated with
preserved systolic function: a common and costly clinical entity. Am Heart J
1998;135:No. 6, Part 2.
14. Black N. Why we need observational studies to evaluate the effectiveness of
health care. BMJ 1996;312:1215–8.
15. Kurland LT, Molgaard CA. The patient record in epidemiology. Sci Am
1981;245:54–63.
16. Melton LJ III. History of the Rochester Epidemiology Project. Mayo Clin
Proc 1996;71:266–74.
17. The SOLVD Investigators. Effect of enalapril on mortality and the devel-
opment of heart failure in asymptomatic patients with reduced left ventric-
ular ejection fractions. N Engl J Med 1992;327:685–91.
18. The Digitalis Investigation Group. The effect of digoxin on mortality and
morbidity in patients with heart failure. N Engl J Med 1997;336:525–33.
173JACC Vol. 33, No. 1 FRIESINGER
January 1999:171–3 EDITORIAL COMMENT
